WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising about 25 to 70 % by weight of the active ingredient of structural formula I



(I)

or a pharmaceutically acceptable salt thereof;
about 25 to 70 % by weight of mannitol or about 25 to 70 % by weight of a mixture of mannitol and microcrystalline cellulose;
about 1 to 5 % by weight of a disintegrant;
about 0 to 5 % by weight of a binding agent; and
about 1 to 3 % by weight of a lubricant.

2. The pharmaceutical composition of Claim 1 wherein said disintegrant is croscarmellose sodium, said binding agent is hydroxypropylcellulose, and said lubricant is magnesium stearate.

3. The pharmaceutical composition of Claim 2 comprising
about 33 to 67 % by weight of said active ingredient;
about 25 to 60 % by weight of mannitol;
about 1 to 4 % by weight of croscarmellose sodium;
about 1 to 4 % by weight of hydroxypropylcellulose; and
about 1 to 2 % by weight of magnesium stearate.

4. The pharmaceutical composition of Claim 3 comprising
about 33 to 67 % by weight of said active ingredient;
about 25 to 60 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;

about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

5. The pharmaceutical composition of Claim 1 additionally comprising about 0 to 0.2 % by weight of an antioxidant.

6. The pharmaceutical composition of Claim 5 wherein said antioxidant is BHT or BHA.

7. The pharmaceutical composition of Claim 2 comprising
about 33 % by weight of said active ingredient;
about 60 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

8. The pharmaceutical composition of Claim 7 additionally comprising about 0.02 % by weight of BHT or BHA.

9. The pharmaceutical composition of Claim 2 comprising
about 33 % by weight of said active ingredient;
about 40 % by weight of mannitol;
about 20 % by weight of microcrystalline cellulose;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

10. The pharmaceutical composition of Claim 9 additionally comprising about 0.02 % by weight of BHT or BHA.

11. The pharmaceutical composition of Claim 2 comprising
about 50 % by weight of said active ingredient;
about 40 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and

about 2 % by weight of magnesium stearate.

12. The pharmaceutical composiion of Claim 11 additionally comprising about 0.02 to 0.03 % by weight of BHT or BHA.

13. The pharmaceutical composition of Claim 2 comprising
about 67 % by weight of said active ingredient;
about 25 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

14. The pharmaceutical composition of Claim 13 additionally comprising about 0.02 % by weight of BHT or BHA.

15. The pharmaceutical composition of Claim 1 prepared by wet granulation methods.

16. A pharmaceutical composition comprising about 33 to 67 % by weight of the active ingredient of structural formula I



(I)

or a pharmaceutically acceptable salt thereof;
about 25 to 60 % by weight of mannitol ;
about 0 to 20 % by weight of microcrystalline cellulose;
about 1 to 5 % by weight of a disintegrant;
about 0 to 5 % by weight of a binding agent; and
about 1 to 3 % by weight of a lubricant.

17. The pharmaceutical composition of Claim 16 wherein said disintegrant is croscarmellose sodium, said binding agent is hydroxypropylcellulose, and said lubricant is magnesium stearate.

18. The pharmaceutical composition of Claim 17 comprising
about 33 to 67 % by weight of said active ingredient;
about 25 to 60 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

19. The pharmaceutical composition of Claim 16 prepared by direct compression methods.

20. A method of inhibiting bone resorption in a human in need thereof comprising orally administering to said human a bone resorption-inhibitory amount of the pharmaceutical composition of Claim 1.

21. A method of treating osteoporosis in a human in need thereof comprising orally administering to said human a therapeutically effective amounnt of the pharmaceutical composition of Claim 1.

22. The pharmaceutical composition of Claim 1 further comprising one or more agents selected from the group consisting of flavoring agents, colorants, and sweeteners.